DualityBio Reports China NMPA Acceptance of BLA for Trastuzumab Pamirtecan in Metastatic HER2+ Breast Cancer

Why It Matters

The acceptance signals a potential new standard of care for HER2‑positive breast cancer in China, where market size and unmet need are substantial. It also validates DualityBio’s next‑generation ADC platform, enhancing its competitive standing globally.

Key Takeaways

• NMPA accepted BLA for T‑Pam in metastatic HER2+ breast cancer
• Interim P‑III data showed significant PFS improvement versus T‑DM1
• T‑Pam is a topoisomerase‑1 inhibitor ADC co‑developed by BioNTech and DualityBio
• US FDA granted Fast Track and Breakthrough designations for endometrial cancer
• Approval could open China market for next‑generation HER2 ADCs

Pulse Analysis

Antibody‑drug conjugates (ADCs) have reshaped treatment paradigms for HER2‑positive cancers, yet most approvals have centered on Western markets. China’s regulatory body, the NMPA, has increasingly streamlined pathways for innovative biologics, recognizing the country’s 300‑million‑patient base and the high prevalence of HER2‑positive breast tumors. By accepting DualityBio’s BLA for trastuzumab pamirtecan, the NMPA signals confidence in the drug’s safety dossier and its potential to address a sizable unmet need, positioning the ADC as a contender alongside established therapies like T‑DM1 and newer entrants such as trastuzumab deruxtecan.

The pivotal DB‑1303‑O‑3001 trial’s interim analysis revealed a clear progression‑free survival (PFS) benefit for T‑Pam over the current standard T‑DM1, marking the first time a topoisomerase‑1 inhibitor ADC has demonstrated superiority in this setting. The statistical significance underscores the therapeutic advantage of delivering a potent DNA‑damaging payload directly to HER2‑expressing cells, potentially translating into longer disease control and improved quality of life for patients who have exhausted first‑line options. Clinicians are likely to view this data as a compelling reason to consider T‑Pam in second‑line regimens, especially given the limited alternatives for refractory HER2‑positive disease.

Strategically, the NMPA acceptance dovetails with DualityBio’s broader growth narrative. The company, in partnership with BioNTech, already enjoys Fast Track and Breakthrough Therapy designations from the US FDA for endometrial cancer, highlighting the platform’s versatility across tumor types. Securing a foothold in China could accelerate revenue generation, bolster the company’s valuation, and provide critical data to support subsequent filings in other regions. Moreover, the move intensifies competition among ADC developers, prompting rivals to accelerate their own pipelines as the market races toward next‑generation HER2‑targeted therapies.